Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: Correlation with cytochrome P450 gene polymorphisms was written by Watari, Shogo;Araki, Motoo;Matsumoto, Jun;Yoshinaga, Kasumi;Sekito, Takanori;Maruyama, Yuki;Mitsui, Yosuke;Sadahira, Takuya;Kubota, Risa;Nishimura, Shingo;Wada, Koichiro;Kobayashi, Yasuyuki;Takeuchi, Hidemi;Tanabe, Katsuyuki;Kitagawa, Masashi;Morinaga, Hiroshi;Kitamura, Shinji;Sugiyama, Hitoshi;Ariyoshi, Noritaka;Wada, Jun;Watanabe, Masami;Watanabe, Toyohiko;Nasu, Yasutomo. And the article was included in Drug Metabolism and Pharmacokinetics in 2021.Product Details of 117976-90-6 The following contents are mentioned in the article:
We evaluated the impact of vonoprazan on blood concentrations of tacrolimus via a retrospective anal. of 52 renal transplant recipients who took tacrolimus and converted from rabeprazole to vonoprazan between August 2018 and Sept. 2019. We compared tacrolimus trough levels upon conversion among groups that were classified based on cytochrome P 450 (CYP) gene polymorphisms. CYP3A5 groups were heterozygous or homozygous for CYP3A5*1 and CYP3A5*3 alleles. CYP2C19 genotypes were classified as extensive (*1/*1), intermediate (*1/*2 and *1/*3) or poor metabolizers (*2/*2, *2/*3 and *3/*3). Tacrolimus trough levels increased only 0.3 ng/mL upon conversion in the CYP3A5*3/*3 group: 5.8 [3.4-7.2] vs 6.1 [3.8-7.9]; p = 0.06. No statistically significance changes in tacrolimus levels also occurred in the CYP3A5*1/*1 or CYP3A5*1/*3 groups. Subgroup analyses of CYP3A5*3/*3 demonstrated low changes for all three CYP2C19 subgroups: 5.2 [4.3-6.5] vs 6.2 [4.3-7.9]; p = 0.07, 6.1 [3.4-7.2] vs 6.7 [4.6-7.9]; p = 0.12 and 5.4 [3.6-6.5] vs 4.7 [3.8-6.3]; p = 1.00, resp. Conversion to vonoprazan thus resulted in little increase of tacrolimus trough levels, even in the group predicted to be most susceptible (CYP3A5*3/*3 and 2C19*1/*1), thus supporting the safety of concomitant use of vonoprazan with tacrolimus. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Product Details of 117976-90-6).
Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3鈥揅6) is higher than in water and generally decreases with a The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Product Details of 117976-90-6
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem